RESUMO
INTRODUCTION: Therapeutic decisions are difficult in elderly patients because of the heterogeneity of this population. Our objective was to evaluate the role of age in the management of patients suffering from primary lung cancer seen in the department of respiratory diseases of the Limoges regional teaching hospital between 2002 and 2004. METHODS: A cross sectional study analysed the management of 363 patients suffering from primary lung cancer. The patients were divided into two groups according to their age (less than seventy or seventy and over). A comparison was made between the management of the two groups. RESULTS: The comparisons according to age produced evidence of reduced activity, greater dependence, an increased Charlson score, less frequently administered radiotherapy and chemotherapy, and more frequent symptomatic treatment in the elderly group (p<0.001). CONCLUSIONS: The geriatric assessment of patients suffering from primary lung cancer should make allowance for the physiological age of the patient and adapt the management to ensure the best quality of life.
Assuntos
Neoplasias Pulmonares/terapia , Fatores Etários , Idoso , Estudos Transversais , Tomada de Decisões , Feminino , Humanos , Neoplasias Pulmonares/mortalidade , Masculino , Estudos RetrospectivosRESUMO
OBJECTIVE: Among obstetricians and midwives, estimate the percentage of smokers, appraise the proportion of medical professionals who mention the subject of nicotine addiction to their pregnant patients, and assess the quality of the information delivered to patients as well as their own experience in the field of tobacology. PATIENTS AND METHODS: Between February and March 2002, 188 postal questionnaires were sent to obstetricians and gynecologists, midwives and midwife students of public hospitals in Limousin and private clinics in Limoges. RESULTS: The response rate was 75,5% (142 answers) and the median age was 37 years old (20-59). 43,6% of the respondents were current smokers. Patients' smoking habits would be asked for and the risks of tobacco smoking would be explained by the majority of praticians and midwives. Minimal counsel to be given was known and given by 34,4% of gynecologists an 26,5% of midwives. Smoking cessation counselling was never proposed by 62% of gynecologists and 79% of midwives. Seventy per cent of them did not have any specific training in the field of tobacology during their studies. DISCUSSION AND CONCLUSION: There seems to be a deficiency in smoking cessation help for pregnant women in Limousin. Specifics programs and trainings for obstetricians, gynecologists, as well as midwives should be organized.
Assuntos
Aconselhamento/métodos , Ginecologia , Tocologia , Obstetrícia , Abandono do Hábito de Fumar , Adulto , Atitude do Pessoal de Saúde , Feminino , Ginecologia/educação , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Pessoa de Meia-Idade , Tocologia/educação , Obstetrícia/educação , Papel do Médico , Gravidez , Cuidado Pré-Natal , Inquéritos e QuestionáriosRESUMO
BACKGROUND: French law and government decisions have induced new development for home base treatments. The objective was to compare cost of home base chemotherapy (HBC) versus outpatient infusions, for non small cell lung cancer (NSCLC). METHODS: 10 patients were selected in each category. D8 of their cycles was performed at home compared to outpatient infusion. Costs were based on national fees with cytostatic drugs as supplement. The real cost was also assessed through a specific questionnaire. RESULTS: 30 D8 infusions were carried out at hospital and 24 D8 infusions at home. Average cost by cycle was 2,829.51 euros [2 560.74-3 147.02] for hospital infusion, 2,372.50 euros [1 962.75-2 792.88] for HBC (-16.15%). Difference was -457.01 euros by cycle [-919.74; 26.82]. Real costs by injection for BHC was 484.42 euros [424.18; 540.32] versus a fee of 699.89 euros [643.64; 750.23]. There were no difference in terms of adverse events. CONCLUSION: HBC for NSCLC is feasible. Average costs by cycle is lower of 16% versus hospital infusion. The results of this non randomized study had to be confirm by further clinical trials.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/economia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Serviços de Assistência Domiciliar/economia , Neoplasias Pulmonares/tratamento farmacológico , Assistência Ambulatorial/economia , Carcinoma Pulmonar de Células não Pequenas/patologia , França , Humanos , Infusões Intravenosas , Neoplasias Pulmonares/patologia , Pessoa de Meia-IdadeRESUMO
INTRODUCTION: We report two cases occurring in 2004 of patients being treated for pleural mesothelioma with a combination of cisplatin or carboplatin and pemetrexed. Investigation by skin tests and flow cytometry confirmed the clinical diagnosis in both cases. CASE REPORTS: Case 1: a man of 62 developed, after 12 courses of cisplatin-pemetrexed, an anaphylactic reaction 5 minutes after the infusion of cisplatin. Treatment was withdrawn permanently. Case 2: a man of 66 developed, after 7 courses of cisplatin-pemetrexed, an anaphylactic reaction within the first minute of the infusion of cisplatin. Subsequently, in March 2004, he received pemetrexed alone without any problems. In August 2004 he was prescribed carboplatin-pemetrexed. Within 5 minutes he developed urticaria, pruritus and abdominal pain. He was treated later with pemetrexed alone with no problems. CONCLUSION: Hypersensitivity to platinum salts usually occurs after several courses of treatment. Skin tests and flow cytometry are a simple, concordant, and reliable way of confirming the diagnosis.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carboplatina/efeitos adversos , Cisplatino/efeitos adversos , Hipersensibilidade a Drogas/etiologia , Idoso , Antimetabólitos Antineoplásicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carboplatina/administração & dosagem , Cisplatino/administração & dosagem , Citometria de Fluxo/métodos , Glutamatos/administração & dosagem , Guanina/administração & dosagem , Guanina/análogos & derivados , Humanos , Masculino , Mesotelioma/tratamento farmacológico , Pessoa de Meia-Idade , Pemetrexede , Neoplasias Pleurais/tratamento farmacológico , Testes Cutâneos/métodosRESUMO
Sclerosing epithelioid fibrosarcoma is a rare tumor recently described. The histological presentation can be confused with certain soft tissue benign tumors and certain sarcomas. Metastatic spread is usually late in the natural course of the disease. We report a case of recurrent sclerosing epithelioid fibrosarcoma with pleural metastases which developed ten years after surgical resection of the primary tumor. The tumor was formed by small uniform round epithelioid cells with a clear cytoplasm. The tumor cells were strongly positive for vimentin. This clinical case is discussed in light of other cases reported in the literature.
Assuntos
Fibrossarcoma/secundário , Neoplasias Pleurais/secundário , Neoplasias de Tecidos Moles/patologia , Idoso , Fibrossarcoma/química , Fibrossarcoma/cirurgia , Humanos , Masculino , Neoplasias Pleurais/química , Neoplasias de Tecidos Moles/cirurgia , Fatores de Tempo , Vimentina/análiseRESUMO
According to physician, Aspirin and NSAIDS hypersensitivity are causing three major problems: how to make the diagnosis? Which treatment are to he given to these patients? What kind of anti-inflammatory drugs are to be prescribed? For these last three years, several articles regarding these matters were being published.
Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Aspirina/efeitos adversos , Hipersensibilidade a Drogas/diagnóstico , Anti-Inflamatórios não Esteroides/imunologia , Aspirina/imunologia , Hipersensibilidade a Drogas/fisiopatologia , HumanosRESUMO
A Phase I trial of carboplatin therapy was performed on patients with locally advanced non-small cell lung cancer who had been previously treated with cisplatin, mitomycin and a vinca aklaloïd. This was administered as a daily bolus infusion or as a continuous infusion for 6 weeks with concurrent daily thoracic radiation. All patients had to be objective responders or to show no change after chemotherapy. The carboplatin was started at 10 mg/m2 per day, and increased to 15 mg/m2 per day and 20 mg/m2 per day, if treatment was feasible in successive cohorts of at least six patients. The radiation therapy consisted of 62-66 Gray on the tumor and the ipsilateral mediastinal nodes, 50 Gray on the mediastinum and 40-45 Gray on the supraclavicular lymph nodes. Twenty-nine patients took part in this study. Thrombocytopenia was the principal dose-limiting toxicity, with 15 mg/m2 per day of bolus or continuous infusion. Other toxicities included a fall in haemoglobin level, a fall in white-blood cell count, nausea and vomiting. The median survival time was 12 months, but the response rate cannot be determined among patients selected on the basis of response to chemotherapy. The recommended Phase II dose for patients previously treated with cisplatin containing chemotherapy, is 10 mg/m2 per day of either a bolus or continuous infusion.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carboplatina/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/radioterapia , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/radioterapia , Radiossensibilizantes/uso terapêutico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carboplatina/efeitos adversos , Cisplatino/administração & dosagem , Terapia Combinada , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mitomicina/administração & dosagem , Radiossensibilizantes/efeitos adversos , Vimblastina/administração & dosagem , Vimblastina/análogos & derivados , Vindesina/administração & dosagem , VinorelbinaRESUMO
The success of transplantation of human embryonic mesencephalic tissue to treat parkinsonian patients is limited by the poor survival of the transplant. We show that an AAV2 vector mediates efficient expression of the egfp reporter gene in organotypic cultures of freshly explanted solid fragments of rat embryonic ventral mesencephalon (VM). We observed early and sustained transgene expression (4 days to > or = 6 weeks). Furthermore, rAAV-infected rat embryonic VM transplanted in the adult striatum continued to express EGFP for > or = 3 months. More than 95% of the transduced cells were neurons. Dopaminergic neurons were transduced at low frequency at earlier time points. This method of gene delivery could prove useful to achieve local, continuous secretion of neurotrophic factors at physiologically relevant doses to treat Parkinson's disease.
Assuntos
Transplante de Tecido Encefálico , Transplante de Tecido Fetal , Transtornos Parkinsonianos/cirurgia , Animais , Dopamina/fisiologia , Expressão Gênica/fisiologia , Vetores Genéticos , Sobrevivência de Enxerto/fisiologia , Proteínas de Fluorescência Verde , Indicadores e Reagentes/metabolismo , Proteínas Luminescentes/genética , Masculino , Mesencéfalo/transplante , Degeneração Neural/fisiopatologia , Técnicas de Cultura de Órgãos , Ratos , Ratos WistarRESUMO
The application of sewage sludge to agricultural land is widely used in France. To determine the impact of sludge treatments, concentrations of Listeria sp., Listeria monocytogenes and faecal indicators were monitored in five types of sludge from three sewage treatment plants in Angers (France) and its suburbs over a 1-year period. On the whole, bacteria were reduced in numbers through sludge treatments. Apart from liming, which leads to reduced levels of bacteria below detection limits, other sludge treatments did not eliminate Listeria sp. and faecal indicators. Listeria sp. and L. monocytogenes were found respectively in 87% and 73% of dewatered sludges and in 96% and 80% of sludges stored in tanks. Concentrations of L. monocytogenes, ranging from 0.15 to 20 MPN g(-1) dry matter in dewatered sludge and from 1 to 240 MPN g(-1) dry matter in sludge stored in tanks, did not show seasonal variations. Spreading of sanitised sludge onto agricultural land results in the addition of 10(6)-10(8) L. monocytogenes per hectare per year, which may contribute to the increase in the dissemination of this pathogenic species in the environment.
Assuntos
Agricultura/métodos , Listeria/isolamento & purificação , Eliminação de Resíduos/métodos , Esgotos/microbiologia , Hidróxido de Cálcio/farmacologia , Enterococcus/isolamento & purificação , Escherichia coli/isolamento & purificação , Fezes/microbiologia , Filtração , França , Listeria/crescimento & desenvolvimento , Listeria monocytogenes/crescimento & desenvolvimento , Listeria monocytogenes/isolamento & purificação , Microbiologia do SoloRESUMO
Pirarubicin (THP) (Roger Bellon Laboratory, France) is a new anthracycline under clinical development. In order to assess the efficacy and toxicity of the drug in small-cell lung carcinoma (SCLC), we have undertaken this trial in front-line therapy in patients with metastatic disease, PS less than 3 and at least one evaluable lesion. Responses were assessed after two cycles of THP (60 mg/m2 i.v. bolus every 3-4 weeks) and a further cross over to VP16 + CDDP (three cycles) was systematic whatever the response to THP. This crossover was performed after only one cycle in case of obvious progression. From June 1988 to April 1990, 32 patients were enrolled: 6 were ineligible (4 non-SCLC, 2 M0), 26 patients were fully evaluable for THP and 18 patients for VP16-CDDP. The characteristics of the patients were as follows: mean age 57.4 years (38-71); T4: 54%; T3: 27%; T2: 19%; N3: 62%; N2: 35%; No: 4%. The efficacy was as follows 1 complete response and 2 partial responses (confirmed by endoscopy); 12 patients received only one cycle because of obvious progression; the overall response rate is 12% (95% confidence interval 0-24%). The patient who had complete response after pirarubicin remained in CR after VP16-CDDP, whereas the 2 patients who had partial response achieved CR for one and PR for the other; among the 15 who did not respond 1 CR and 7 PR were observed. The only significant toxicity of THP was granulopenia without infection. THP seems to be an effective anthracycline in SCLC, and the study is continuing. A response could be reached in 50% of the nonresponders with standard therapy and 10 of 24 patients (42%) finally responded. Therefore, this schedule for testing new drugs in metastatic SCLC appears ethically acceptable.
Assuntos
Carcinoma de Células Pequenas/tratamento farmacológico , Carcinoma de Células Pequenas/secundário , Doxorrubicina/análogos & derivados , Neoplasias Pulmonares/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Pequenas/mortalidade , Carcinoma de Células Pequenas/patologia , Cisplatino/administração & dosagem , Doxorrubicina/administração & dosagem , Doxorrubicina/efeitos adversos , Doxorrubicina/uso terapêutico , Esquema de Medicação , Avaliação de Medicamentos , Etoposídeo/administração & dosagem , Feminino , Humanos , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Indução de Remissão , Taxa de SobrevidaRESUMO
UNLABELLED: Between February 1992 and May 1993, 22 patients older than 75 years, with non small cell lung cancer, were treated with carboplatin and oral etoposide. There were 18 men and four women with a median age of 79 years. Fourteen patients had an epidermoid carcinoma: four had an adenocarcinoma and four had an undifferentiated carcinoma. Carboplatin was administered intravenously on day 1 at a dose of 300 mg/m2; oral etoposide was administered at a dose of 600 mg/m2 (two capsules daily) for 9, 10, 11, or 12 days according to body surface. Courses were repeated every 28 days for a total of three courses. TOXICITY: 15 patients (68%) had received previous chemotherapy. Myelosuppression was the main problem with one grade IV and five grade III hematologic toxicities. We observed one mild neurologic toxicity. RESULTS: 19 patients were evaluable for response. We observed one complete response (5%), five disease stabilizations (26%) and 13 disease progressions. Median survival was 5 months. These results led to discontinue this study.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carboplatina/administração & dosagem , Relação Dose-Resposta a Droga , Etoposídeo/administração & dosagem , Feminino , Seguimentos , França , Doenças Hematológicas/induzido quimicamente , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de NeoplasiasRESUMO
Pets must be considered allergy factors. They are not advised for atopic families. However some recent publications suggest a protective effect of cat and dog exposure in the first year of life. The origin of this protective effect is not known.
Assuntos
Animais Domésticos , Hipersensibilidade Respiratória/etiologia , Adolescente , Adulto , Animais , Gatos , Criança , Pré-Escolar , Cães , Poeira , Endotoxinas/efeitos adversos , Exposição Ambiental , Estudos Epidemiológicos , Cabelo , Humanos , Imunoglobulina G/imunologia , Lactente , Prevalência , Hipersensibilidade Respiratória/epidemiologiaRESUMO
107 patients have discontinued Hymenoptera venom immunotherapy between 1988 and 2000. 31 have been seen again with intradermal tests with IgEs, and 81 responded to a questionnaire. Intradermal reactions and IgEs decrease together significantly during immunotherapy and then persist at low level during three years. Beyond, the number of patients is insufficient. 32 patients were stung by the same Hymenoptera and not had any systemic reaction. However, five have beta blockers, three have IEC and half of the patients don't take precautions to avoid Hymenoptera.
Assuntos
Venenos de Abelha/uso terapêutico , Dessensibilização Imunológica , Mordeduras e Picadas de Insetos/imunologia , Venenos de Vespas/uso terapêutico , Adolescente , Antagonistas Adrenérgicos beta/uso terapêutico , Adulto , Animais , Antialérgicos/uso terapêutico , Venenos de Abelha/efeitos adversos , Venenos de Abelha/imunologia , Feminino , Seguimentos , Humanos , Himenópteros , Imunoglobulina E/sangue , Mordeduras e Picadas de Insetos/tratamento farmacológico , Mordeduras e Picadas de Insetos/epidemiologia , Testes Intradérmicos , Masculino , Pessoa de Meia-Idade , Recidiva , Estudos Retrospectivos , Inquéritos e Questionários , Resultado do Tratamento , Venenos de Vespas/efeitos adversos , Venenos de Vespas/imunologiaRESUMO
BACKGROUND: Although asthma is the most common pulmonary condition in pediatrics, the incidence of exercise-induced asthma (EIA) in school children is not well documented and few studies have been devoted to the condition. There are considerable variations in morbidity and mortality between countries. This study was designed to evaluate the prevalence of EIA in children in the 6th grade (11-14 year-olds) in one French department (Haute-Vienne) and to identify undiagnosed cases. METHODS: The representative sample was obtained over a period of 28 days (February 2(nd) to April 10(th) 1998) by cluster sampling method, stratified by size of the schools. The number of subjects planned was 891. The selected children filled in a questionnaire on their asthma history and were subjected to an outdoor exercise test (6 minute run). Respiratory function was measured with a peak flow-meter. RESULTS: Seven hundred and eighty two school children were included in this survey. Participation rate was 87.8%. The prevalence of asthma from the questionnaire was 10.7% (CI 95%: 8.7 - 12.8). After exercise, 68 school children presented exercise-induced bronchospasm: the prevalence of the EIA was 8.7% (CI 95%: 6.9 - 10.5). Among these 68 school children, 27 were known asthmatics and 41 were not. With the 10 treated asthmatics, the overall prevalence of EIA was therefore estimated at 9.9% (CI 95%: 8.2 - 11.7). CONCLUSION: The prevalence of asthma and EIA was close to that found in other studies using a similar methodology. EIA remains under-diagnosed since 41 undeclared asthmatic school children were identified in our population. Nurses'information is necessary to initiate the use of systematically testing respiratory function (with a peak flow meter) at least once a year. Efficient management of the asthmatic child requires cooperation between the various professionals dealing with school children.
Assuntos
Asma Induzida por Exercício/epidemiologia , Adolescente , Fatores Etários , Asma Induzida por Exercício/diagnóstico , Criança , Análise por Conglomerados , Estudos Transversais , Interpretação Estatística de Dados , Feminino , França/epidemiologia , Inquéritos Epidemiológicos , Humanos , Masculino , Testes de Função Respiratória , Estudos de Amostragem , Inquéritos e QuestionáriosRESUMO
The domiciliary treatment of severe chronic respiratory failure (I.R.C.) by oxygen or assisted ventilation was accomplished by members of a recently created national organisation (ANTA-DIR, 1980). This work reports the results of a survey carried out in Nice on 19 patients (12 men and 7 women) followed for more than a year. A questionnaire was filled in at the home of each patient, primarily to assess the functional outcome and the level of compliance of the therapy prescribed. We noticed and 86% drop in the number of days spent in hospital over a 2 year period. An analysis of the diary cards on the use of respiratory equipment, as well as oxygen consumption compared to the therapy initially prescribed, allowed an analysis of the degree of patient compliance. This was very good in only 3 out of 19 subjects and on average the prescribed therapy was followed for only two thirds of the time. However, a functional evaluation using simple clinical criteria showed a discernible improvement in 11 patients, who had a better quality of life and a greater autonomy since coming under supervision.
Assuntos
Pneumopatias Obstrutivas/complicações , Cooperação do Paciente , Respiração Artificial/psicologia , Insuficiência Respiratória/terapia , Idoso , Dependência Psicológica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Oxigenoterapia/psicologia , Qualidade de Vida , Testes de Função Respiratória , Insuficiência Respiratória/diagnóstico , Insuficiência Respiratória/etiologia , Estudos Retrospectivos , Ajustamento SocialRESUMO
We report two cases of death from acute respiratory insufficiency of tuberculous origin. There were rare clinical presentations in which the clinical and radiological aspects were particularly atypical, suggesting a diagnosis of an acute respiratory distress syndrome. Bacteriological confirmation is necessary but it is worth considering this aetiology with each case of unexplained respiratory distress because the mortality is high and the prognosis is related to how early drug therapy is given.
Assuntos
Síndrome do Desconforto Respiratório/etiologia , Tuberculose Pulmonar/complicações , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Gemcitabine is used to treat solid tumours such as non small-cell lung cancer. In general, it is a well tolerated cytotoxic agent and myelosuppression is the major dose limiting side-effect. Pulmonary toxicity has been described and dyspnoea occurs in approximately 8% of patients in whom, for the majority, it is mild and reversible. But several cases of acute respiratory distress syndrome (ARDS) related to Gemcitabine treatment have been reported since 1997 and a few were fatal. We present a case of Gemcitabine toxicity in a patient treated for a lung cancer. He presented with a respiratory distress syndrome due to acute interstitial pneumonitis from which he promptly recovered with corticosteroid therapy.
Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Desoxicitidina/análogos & derivados , Desoxicitidina/efeitos adversos , Doenças Pulmonares Intersticiais/induzido quimicamente , Neoplasias Pulmonares/tratamento farmacológico , Corticosteroides/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Antimetabólitos Antineoplásicos/uso terapêutico , Desoxicitidina/uso terapêutico , Humanos , Doenças Pulmonares Intersticiais/tratamento farmacológico , Masculino , Síndrome do Desconforto Respiratório/etiologia , GencitabinaRESUMO
Radon is a noble gas derived from the decay of radium, which itself is a decay product of uranium. The decay products of radon can collect electrostatically on dust particles in the air and, if these particles are inhaled and attach to bronchial epithelium, produce a high local radiation dose. Alpha particles can induce DNA double-strand breaks and the development of cancer. A causal relation between lung cancer and radon exposure and its progeny has been demonstrated in epidemiological studies of miners. Radon exposure became a public health issue almost 15 years ago. Most radon exposure occurs indoors, predominantly in the home. There is however, a wide range of radon concentration values in different countries. The highest level occurs in areas with granite and permeable soils. The risk for smoking, the leading cause of lung cancer, is far greater than for radon, the second leading cause. The estimates obtained from case-control studies of indoor radon are very contradictory. Scientific knowledge of effects of low levels of exposure to radon and the role of cigarette smoking, as a combined factor, must be studied. Smoking and radon probably interact in a multiplicative fashion.
Assuntos
Poluentes Radioativos do Ar/efeitos adversos , Carcinógenos Ambientais/efeitos adversos , Exposição Ambiental/efeitos adversos , Habitação , Radônio/efeitos adversos , Movimentos do Ar , Poluentes Radioativos do Ar/análise , Carcinógenos Ambientais/análise , Estudos de Casos e Controles , Causalidade , Exposição Ambiental/análise , França/epidemiologia , Humanos , Neoplasias Pulmonares/induzido quimicamente , Neoplasias Pulmonares/epidemiologia , Saúde Pública , Radônio/análise , Produtos de Decaimento de Radônio/efeitos adversos , Produtos de Decaimento de Radônio/análise , Dióxido de Silício , Fumar/efeitos adversos , Solo/análiseRESUMO
A patient with primary pulmonary artery hypertension diagnosed by pulmonary arterial catheterisation, angiography and lung biopsy was the subject of several therapeutic trials of vasodilators. The short term and long term results over the next four years were on the whole disappointing. The type of study protocole used is discussed, as are the risks and cost.
Assuntos
Hipertensão/tratamento farmacológico , Vasodilatadores/uso terapêutico , Biópsia , Cateterismo Cardíaco , Hemodinâmica/efeitos dos fármacos , Humanos , Hipertensão/diagnóstico , Hipertensão/patologia , Pulmão/patologia , Masculino , Pessoa de Meia-Idade , Circulação Pulmonar/efeitos dos fármacosRESUMO
OBJECTIVE: To demonstrate the feasibility of administration Tegeline at home from a point of view of efficacy, safety, tolerance, to validate the pertinence of the selection and the training of patients who could benefit from this type of administration and to assess the long term efficacy and safety. METHOD: This retrospective study was conducted in patients exhibiting primary immune deficiency and formerly treated with intravenous immunoglobulins at least six months in hospital settings, trained by the centre for the training of children in the home (Centre de formation au traitement à domicile de l'enfant--CFTDE) and having received at least one administration of Tegeline at home from January 1st 2000. Tegeline contains a mean of 97.6% of whole IgG (58.8% of IgG1, 34.1% of IgG2, 5.4% of IgG3 and 1.7% of IgG4). RESULTS: Two hundred and eighteen follow-up sheets were completed by 13 patients in whom all the eligibility criteria were fulfilled. The total number of infusions per patient ranged from 4 to 41. No difficulty in administration was reported in 10 patients, difficulties in placing the needle were encountered in 3 other patients and motivating their return to the hospital for treatment (after 6 and 10 months) in 2 cases. The infusion flow rate was usually of 2 to 3 ml/kg/h. During the follow-up period, no episode of infection was noted in 5 patients and 8 presented infections that were treated with antibiotics. Regarding safety, the security 'kits' (corticosteroids, adrenalin) that were supplied to each patient were never used. Over time, the median duration of the infusions at home was of 5 years and 6 months. CONCLUSION: In trained and selected patients, this study demonstrated the efficacy, safety and tolerance to the administration of Tegeline at home.